山东医药

参考文献

[1]《原发性骨质疏松症诊疗社区指导原则》编写组.原发性骨质疏松症社区诊疗指导原则[J].中国全科医学，2019,22(10):1125-1132.

[2]SALARI N,GHASEMI H,MOHAMMADI L,et al.The global prevalence of osteoporosis in the world:a comprehensive systematic review and meta-analysis[J].J Orthop Surg Res,2021,16(1):609.

[3]DOMAZETOVIC V,MARCUCCI G,IANTOMASI T,et al.Oxidative stress in bone remodeling:role of antioxidants[J].Clin Cases Miner Bone Metab,2017,14(2):209-216.

[4]COLLABORATORS G B D,LAZARUS J,OTOIU A.Global burden of 87 risk factors in 204 countries and territories,1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J].Lancet,2020,396(10258):1223-1249.

[5]YOSHIMURA N,MURAKI S,OKA H,et al.Prevalence of knee osteoarthritis,lumbar spondylosis,and osteoporosis in Japanese men and women:the research on osteoarthritis/osteoporosis against disability study[J].J Bone Miner Metab,2009,27(5):620-628.

[6]WRIGHT N C,LOOKER A C,SAAG K G,et al.The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine[J].J Bone Miner Res,2014,29(11):2520-2526.

[7]SARAFRAZI N,WAMBOGO E A,SHEPHERD J A.Osteoporosis or low bone mass in older adults:united states,2017-2018[J].NCHS Data Brief,2021,3(405):1-8.

[8]BABHULKAR S,SETH S S.Prevalence of osteoporosis in India:an observation of 31238 adults[J].Int J Res Orthop,2021,7(2):362.

[9]MITHAL A,KAUR P.Osteoporosis in Asia:a call to action[J].Curr Osteoporos Rep,2012,10(4):245-247.

[10]WILLERS C,NORTON N,HARVEY N C,et al.Osteoporosis in Europe:a compendium of country-specific reports[J].Arch Osteoporos,2022,17(1):23.

[11]WANG Y,TAO Y,HYMAN M E,et al.Osteoporosis in China[J].Osteoporos Int,2009,20(10):1651-1662.

[12]CHEN P,LI Z,HU Y.Prevalence of osteoporosis in China:a meta-analysis and systematic review[J].BMC Public Health,2016,16(1):1039.

[13]《原发性骨质疏松症诊疗社区指导原则》编写组.中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J].中华骨质疏松和骨矿盐疾病杂志，2019,12(4):317-318.

[14]朱洁云，高敏，宋秋韵，等.中国老年人骨质疏松症患病率的Meta分析[J].中国全科医学，2022,25(3):346-353.

[15]吴惠一，刘颖，兰亚佳，等.中国绝经女性骨质疏松症患病率的Meta分析[J].中国循证医学杂志，2022,22(8):882-890.

[16]GREGSON C L,ARMSTRONG D J,BOWDEN J,et al.UKclinical guideline for the prevention and treatment of osteoporosis[J].Arch Osteoporos,2022,17(1):58.

[17]SANCHEZ-RODRIGUEZ D,BERGMANN P,BODY J J,et al.The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women[J].Maturitas,2020,139:69-89.

[18]GUIDELINES-GYNECOLOGY C O C P.Osteoporosis prevention,screening,and diagnosis:ACOG Clinical Practice Guideline No.1[J].Obstet Gynecol,2021,138(3):494-506.

[19]KHAN A A,ALROB H A,ALI D S,et al.Guideline No.422g:menopause and osteoporosis[J].J Obstet Gynaecol Can,2022,44(5):527-536.

[20]中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.原发性骨质疏松症基层诊疗指南（2019年）[J].中华全科医师杂志，2020,19(4):304-315.

[21]中国营养学会骨营养与健康分会，中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症患者的营养和运动管理专家共识[J].中华骨质疏松和骨矿盐疾病杂志，2020,13(5):396-410.

[22]ORIMO H,NAKAMURA T,HOSOI T,et al.Japanese 2011guidelines for prevention and treatment of osteoporosis--executive summary[J].Arch Osteoporos,2012,7(1):3-20.

[23]PINKERTON J V,CHELMOW D,WITKOP C T.Management of postmenopausal osteoporosis:ACOG Clinical Practice Guideline No.2[J].OBSTET GYNECOL,2022,139(4):698-717.

[24]CAMACHO P M,PETAK S M,BINKLEY N,et al.American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update[J].Endocr Pract,2020,26:1-46.

[25]KANIS J A,COOPER C,RIZZOLI R,et al.European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J].Osteoporos Int,2019,30(1):3-44.

[26]FERRARI S,LIPPUNER K,LAMY O,et al.2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO)[J].Swiss Med Wkly,2020,150(3940):20352.

[27]乔林，熊英，徐克惠.“中国绝经管理和绝经激素治疗指南（2018）”解读[J].实用妇产科杂志，2019,35(3):184-187.

[28]马远征，王以朋，刘强，等.中国老年骨质疏松诊疗指南（2018)[J].中国老年学杂志，2019,39(11):2557-2575.